Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on February 25th and 26th, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Songjiang Ma, President of Gyre Therapeutics, sold 2,000 shares of common stock on February 25, 2025, at a weighted average price of $11.37.
- An additional 2,000 shares were sold on February 26, 2025, at a weighted average price of $11.63.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Following these transactions, Mr. Ma indirectly owns 2,855,260 shares through his spouse.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting the sale of shares by an officer. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.
Industry Context
Sales by company presidents are common and often pre-planned to avoid insider trading accusations. The use of a 10b5-1 plan suggests the sales were arranged in advance.
Stakeholder Impact
- The sale of shares by a company president could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 09/13/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 02/25/2025 | Date of first transaction: Sale of 2,000 shares |
| 02/26/2025 | Date of second transaction: Sale of 2,000 shares |
| 02/27/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.